The HEART Score and HEART Pathway Clinical Decision Protocol

Clinical Risk Stratification: HEART Score versus HEART Pathway

• The evaluation of adult patients presenting with suspected Acute Coronary Syndrome (ACS) requires distinguishing between risk assessment tools and actionable clinical decision algorithms.

• HEART Score: A clinical prediction tool that estimates a patient's risk of experiencing a Major Adverse Cardiac Event (MACE) within a 6-week period.

  • MACE is defined as acute myocardial infarction (MI), the need for coronary revascularization (percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG]), or all-cause cardiac death.

  • The HEART score does not serve as a chest-pain clearance test and does not answer the absolute question, "Does this patient have ACS right now?"

• HEART Pathway: A clinical decision protocol that integrates the initial HEART score with serial biomarker testing (high-sensitivity troponin) and repeat electrocardiograms (ECGs) to direct disposition (discharge, observation, advanced diagnostic testing, or inpatient admission).

  • Clinical Workflow: Risk Assessment $\rightarrow$ Serial Testing $\rightarrow$ Clinical Action/Disposition.

  • A low HEART score alone is never a final disposition; disposition requires completing the pathway.

The HEART Score Components and Scoring System

• The HEART score assigns a value of $0$, $1$, or $2$ points to five distinct clinical domains, resulting in a total score ranging from $0$ to $10$ points.

• H – History:

  • $0\text{ points}$: Slightly suspicious for cardiac ischemia.

  • $1\text{ point}$: Moderately suspicious for cardiac ischemia.

  • $2\text{ points}$: Highly suspicious for cardiac ischemia.

• E – Electrocardiogram (ECG):

  • $0\text{ points}$: Normal ECG.

  • $1\text{ point}$: Nonspecific repolarization abnormalities, left ventricular hypertrophy (LVH), or bundle branch block.

  • $2\text{ points}$: Significant ST-segment depression or dynamic T-wave changes.

• A – Age:

  • $0\text{ points}$: Age $< 45\text{ years}$.

  • $1\text{ point}$: Age $45 - 64\text{ years}$.

  • $2\text{ points}$: Age $\ge 65\text{ years}$.

• R – Risk Factors:

  • Risk factors evaluated include: current hypertension, hyperlipidemia, diabetes mellitus, active or recent smoking history, family history of premature coronary artery disease (CAD), obesity, or documented atherosclerotic vascular disease (e.g., prior MI, stroke, peripheral arterial disease).

  • $0\text{ points}$: No known risk factors.

  • $1\text{ point}$: $1$ or $2$ cardiac risk factors.

  • $2\text{ points}$: $\ge 3$ risk factors OR documented history of atherosclerotic vascular disease.

• T – Troponin (Initial Presentation):

  • $0\text{ points}$: Initial cardiac troponin level at or below the normal limit / assay cutoff.

  • $1\text{ point}$: Initial cardiac troponin level elevated $1 - 3\times$ above the upper reference limit.

  • $2\text{ points}$: Initial cardiac troponin level elevated $> 3\times$ above the upper reference limit.

High-Sensitivity Cardiac Troponin (hs-cTn) Protocols and Delta Calculations

• Modern clinical pathways rely on high-sensitivity cardiac troponin (hs-cTn) assays integrated into accelerated diagnostic protocols.

• Protocol Timing: Institutional protocols utilize rapid testing schedules, typically taking initial blood samples at arrival ($0\text{ hour}$) and repeat samples at $1 - 2\text{ hours}$ ($0/1\text{-hour}$ or $0/2\text{-hour}$ strategies).

• Delta ($\Delta$) Troponin Calculation:   $\Delta\,\text{troponin} = \text{repeat hs-cTn} - \text{initial hs-cTn}$

• Interpretation of hs-cTn Values and Delta ($\Delta$):

  • Low Baseline + Minimal/No $\Delta$: Reassuring pattern meeting validated rule-out criteria for acute myocardial infarction.

  • Rising or Falling $\Delta$: Indicates acute myocardial injury; requires prompt evaluation for Acute Myocardial Infarction (AMI) or other acute cardiovascular emergencies.

  • Elevated Baseline + Flat $\Delta$ (Minimal Change): Suggests chronic myocardial injury (e.g., chronic heart failure, renal dysfunction, severe left ventricular hypertrophy).

The Low-Risk HEART Pathway (Score 0 to 3)

• Patients with a HEART score of $0 - 3$ are classified as Low Risk for ACS/MACE.

• Requirements for Safe Emergency Department (ED) Discharge:

  • Completion of serial high-sensitivity troponin testing ($0/1\text{-hour}$ or $0/2\text{-hour}$ protocol) meeting assay-specific rule-out threshold values with no significant delta ($\Delta$).

  • Absence of new or dynamic ischemic changes on repeat electrocardiograms.

  • Complete clinical stability and resolution of unstable symptoms.

  • Execution of shared decision-making with the patient.

  • Outpatient follow-up arranged within $1 - 2\text{ weeks}$.

  • Clear, explicit return precautions provided to the patient.

• The Three Critical Clinical "Off-Ramps" from Discharge:

  • A patient with a HEART score of $0 - 3$ cannot be safely discharged if any of the following occur:

  1. Troponin Off-Ramp: Serial hs-cTn fails to meet rule-out criteria (elevated baseline or significant delta $\Delta$).

  2. ECG Off-Ramp: Development of new or dynamic ischemic changes on serial ECGs.

  3. Symptom/Clinical Off-Ramp: Persistent or recurrent concerning chest pain episodes, unstable vital signs, or clinical instability.

  • Management of Off-Ramp Patients: Immediately transition out of the low-risk discharge pathway and re-categorize into the Intermediate-Risk or High-Risk pathway based on findings.

The Intermediate-Risk HEART Pathway (Score 4 to 6)

• Patients with a HEART score of $4 - 6$ fall into the Intermediate Risk category.

• Intermediate risk represents a clinical decision point rather than a fixed rule-out algorithm.

• Three Risk Assessment Categories for Intermediate Patients:

  • Symptoms and ECG: Ongoing or recurrent concerning symptoms, dynamic ECG shifts, or hemodynamic instability elevate risk.

  • Troponin Dynamics: Elevated baseline hs-cTn or significant delta ($\Delta$) mandates moving away from standard discharge.

  • Coronary History: Known CAD, prior PCI, prior CABG, or abnormal prior functional/anatomic testing shifts management focus.

• Core Diagnostic Questions for Intermediate Patients:

  • When serial hs-cTn levels are negative/flat, the central clinical question shifts from "Is the patient having an acute myocardial infarction right now?" to "Does this patient have underlying coronary artery disease or inducible ischemia that requires non-invasive diagnostic testing?"

  • Anatomic Evaluation: Coronary Computed Tomography Angiography (CCTA) addresses whether significant coronary artery plaques or stenoses are present.

  • Functional Evaluation: Non-invasive stress testing (e.g., nuclear stress, stress echocardiography) addresses whether coronary lesions cause inducible myocardial ischemia.

• Disposition Strategies:

  • Observation unit evaluation (e.g., chest pain unit) for serial monitoring and non-invasive testing.

  • Inpatient admission when clinical uncertainty, elevated risk, or co-morbidities exist.

  • Outpatient evaluation: Permissible only in selected patients who are clinically stable, have completely reassuring serial hs-cTn and ECG evaluations, have no high-risk clinical features, have reliable access to timely follow-up, and undergo shared decision-making.

  • Cardiology consultation is integrated when diagnostic interpretation, test selection, known complex CAD, persistent symptoms, or disposition decisions remain unclear.

The High-Risk HEART Pathway (Score 7 to 10)

• Patients scoring $\ge 7$ (range $7 - 10$) are classified as High Risk.

• The HEART pathway for high-risk patients is designed to direct active ACS treatment and inpatient disposition, not to identify patients for ED discharge.

• Management Guidelines for High-Risk Patients:

  • Initiate active ACS medical management (unless contraindicated):

  • Aspirin administration.

  • Anti-ischemic therapies (e.g., nitrates, beta-blockers as clinically appropriate).

  • Anticoagulation and guideline-directed medical therapy.

  • Urgent Cardiology consultation.

  • Inpatient admission for inpatient management and monitoring.

  • Evaluation for an early invasive strategy (e.g., diagnostic cardiac catheterization and PCI) based on clinical risk features.

• Key Diagnostic Distinctions:

  • A high HEART score ($\ge 7$) is a risk marker, not a definitive diagnosis of ACS or NSTEMI by itself.

  • A high HEART score does not automatically trigger cardiac catheterization laboratory activation; lab activation requires specific clinical, electrocardiographic (e.g., STEMI), or hemodynamically unstable ACS parameters.

  • Acute Myocardial Infarction (NSTEMI) requires demonstrating acute myocardial injury (rising and/or falling troponin values with at least one value above the 99th percentile upper reference limit) alongside clinical or electrocardiographic evidence of ischemia.

Comprehensive HEART Pathway Decision Algorithm

• Inclusion Criteria: Adult presenting with suspected ACS after initial stabilization, without STEMI or immediate indications for emergency reperfusion, and without obvious alternative life-threatening diagnoses.

• Algorithm Workflow summary:

  • Step 1: Calculate HEART Score ($0 - 10$ points).

  • Step 2: Risk Grouping:

  • Low Risk ($0 - 3$)

  • Intermediate Risk ($4 - 6$)

  • High Risk ($\ge 7$)

  • Step 3: Serial Testing (hs-cTn at $0\text{ hr}$ and $1 - 2\text{ hrs}$ + serial ECGs).

  • Step 4: Path-Specific Actions:

  • Low Risk ($0 - 3$) + Negative Serial Testing + Clinically Stable $\rightarrow$ Consider ED Discharge with shared decision-making and follow-up within $1 - 2\text{ weeks}$.

  • Intermediate Risk ($4 - 6$) OR Low Risk with abnormal serial testing $\rightarrow$ Further Risk Assessment (CCTA, stress testing, observation, cardiology consultation, or targeted outpatient follow-up).

  • High Risk ($\ge 7$) $\rightarrow$ Treat as ACS, initiate medical therapy, obtain cardiology consultation, and admit for inpatient evaluation/management.

Exam Expectations versus Clinical Practice Realities

• Exam Assessment Principles:

  • Focuses on understanding the structured decision rule and clinical logic rather than memorizing raw assay cutoffs.

  • Clinical vignettes explicitly provide qualitative descriptions (e.g., whether history is "moderately" or "highly" suspicious, or whether ST depression is significant).

• Comparison Table:

Clinical Case Studies

Case 1: Maria Alvarez (Intermediate Risk Evaluation)

• Presentation: $58\text{-year-old}$ female presenting with intermittent substernal chest pressure for $2\text{ days}$. Describes tightness occurring while walking uphill or carrying groceries, resolving after several minutes of rest. Today experienced an episode lasting $15\text{ minutes}$. Pain-free on arrival.

• Medical History: Hypertension, hyperlipidemia. Medications: Lisinopril, Atorvastatin. Non-smoker. No prior history of CAD.

• Physical Exam & Vitals: Stable and within normal limits.

• HEART Score Calculation:

  • History: Moderately suspicious ($1\text{ point}$).

  • ECG: Nonspecific ST-T wave changes ($1\text{ point}$).

  • Age: $58\text{ years}$ ($1\text{ point}$).

  • Risk Factors: HTN + HLD ($1\text{ point}$).

  • Troponin: Initial normal ($0\text{ points}$).

  • Total Score: $4\text{ points}$ (Intermediate Risk).

• Serial Evaluation & Clinical Decision-Making:

  • Repeat ECG shows no dynamic changes; repeat hs-cTn remains flat and within rule-out range; patient remains pain-free.

  • Clinical Reasoning: Reassuring serial troponins rule out acute myocardial infarction occurring at this moment, but do not rule out underlying significant CAD driving exertional symptoms.

  • Impact of Historical Variants: If Maria had a prior PCI with a drug-eluting stent to the LAD $3\text{ years}$ ago, or developed recurrent pain walking in the ED, she shifts out of routine low-threshold disposition into structured observation or inpatient admission. Conversely, if CCTA performed $18\text{ months}$ ago demonstrated zero coronary plaque or stenosis, the clinical concern for epicardial CAD is drastically reduced.

Case 2: Robert Chen (High Risk Management)

• Presentation: $67\text{-year-old}$ male presenting with severe substernal pressure while shoveling snow, radiating to his left arm, accompanied by diaphoresis and nausea. Pain improved slightly with rest but has not resolved. History of peripheral arterial disease (PAD).

• Risk Factors: Hypertension, diabetes mellitus, hyperlipidemia, $30\text{ pack-year}$ smoking history, age $67\text{ years}$.

• HEART Score Calculation Breakdown:

• Laboratory & Serial Findings:

  • Initial ($0\text{-hr}$) hs-cTn: $38\,\text{ng/L}$.

  • Repeat ($1\text{-hr}$) hs-cTn: $71\,\text{ng/L}$.

  • Calculated Delta: $\Delta = +33\,\text{ng/L}$.

• Diagnostic Conclusion & Plan:

  • Rising hs-cTn ($\Delta = +33\,\text{ng/L}$) combined with ischemic ECG changes and clinical symptoms meets criteria for Acute Myocardial Injury with Ischemia (NSTEMI).

  • Action: Immediate initiation of ACS therapy (Aspirin, anti-ischemic medications, anticoagulation), inpatient admission, urgent Cardiology consultation, and evaluation for early invasive management.

Case 3: Brad 'Dissection' Robson (Diagnostic Tool Limitations)

• Presentation: $50\text{-year-old}$ male with hypertension and diabetes presenting with severe chest pain. History characterized as moderately suspicious for ACS. ECG displays nonspecific repolarization changes.

• Laboratory Findings: Initial troponin $0.05\,\text{ng/L}$ (normal baseline, cutoff $>0.1\,\text{ng/L}$).

• HEART Score Calculation:

  • History: Moderately suspicious ($1\text{ point}$).

  • ECG: Nonspecific changes ($1\text{ point}$).

  • Age: $50\text{ years}$ ($1\text{ point}$).

  • Risk Factors: HTN + DM ($1\text{ point}$).

  • Troponin: Normal ($0\text{ points}$).

  • Total HEART Score: $4\text{ points}$ (or calculated as $3\text{ points}$ in low-risk baseline testing).

• Final Diagnosis: Acute Aortic Dissection.

• Critical Takeaway: The HEART score specifically evaluates the probability of ACS and 6-week MACE. A low or intermediate HEART score does not rule out non-coronary vascular or pulmonary life-threatening causes of chest pain (such as aortic dissection, pulmonary embolism, tension pneumothorax, or esophageal rupture). Clinical evaluation for non-ACS life threats must always precede reliance on the HEART Pathway.

Critical Takeaways and Diagnostic Caveats

• MACE Prediction: The HEART score predicts 6-week MACE risk; it is not a binary rule-in/rule-out tool for chest pain.

• Low Risk Risk Status: A low score ($0 - 3$) indicates low risk, not zero risk. Discharged patients still require risk factor modification and outpatient follow-up within $1 - 2\text{ weeks}$.

• Serial Evaluation Requirement: A single negative troponin measurement can never rule out ACS. Serial troponins and repeat ECGs are mandatory components of the HEART Pathway.

• Intermediate Risk Meaning: A score of $4 - 6$ indicates that the diagnostic evaluation is incomplete; it requires active clinical risk assessment (CCTA, stress testing, observation) rather than automated discharge.

• High Score Action: A high score ($\ge 7$) identifies a high-risk patient requiring admission and inpatient ACS management; it does not independently activate the cardiac catheterization laboratory without diagnostic STEMI/ACS criteria.

• Universal Principle: Always evaluate the patient for immediate alternative life-threatening chest pain causes before applying the HEART Pathway.